These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28460430)

  • 1. Metabolic heterogeneity signature of primary treatment-naïve prostate cancer.
    Lin D; Ettinger SL; Qu S; Xue H; Nabavi N; Choi SYC; Bell RH; Mo F; Haegert AM; Gout PW; Fleshner N; Gleave ME; Pollak M; Collins CC; Wang Y
    Oncotarget; 2017 Apr; 8(16):25928-25941. PubMed ID: 28460430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic deregulation in prostate cancer.
    Srihari S; Kwong R; Tran K; Simpson R; Tattam P; Smith E
    Mol Omics; 2018 Oct; 14(5):320-329. PubMed ID: 30215656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia.
    Haider S; McIntyre A; van Stiphout RG; Winchester LM; Wigfield S; Harris AL; Buffa FM
    Genome Biol; 2016 Jun; 17(1):140. PubMed ID: 27358048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
    Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a predictive model for stromal content in prostate cancer samples to improve signature performance.
    Boufaied N; Takhar M; Nash C; Erho N; Bismar TA; Davicioni E; Thomson AA
    J Pathol; 2019 Dec; 249(4):411-424. PubMed ID: 31206668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer.
    Alshalalfa M; Schliekelman M; Shin H; Erho N; Davicioni E
    Biol Cell; 2015 Jul; 107(7):232-44. PubMed ID: 25900404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.
    Zhao SG; Jackson WC; Kothari V; Schipper MJ; Erho N; Evans JR; Speers C; Hamstra DA; Niknafs YS; Nguyen PL; Schaeffer EM; Ross AE; Den RB; Klein EA; Jenkins RB; Davicioni E; Feng FY
    Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):229-36. PubMed ID: 25986914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reference-free transcriptome signatures for prostate cancer prognosis.
    Nguyen HTN; Xue H; Firlej V; Ponty Y; Gallopin M; Gautheret D
    BMC Cancer; 2021 Apr; 21(1):394. PubMed ID: 33845808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy.
    Kohli M; Wang L; Xie F; Sicotte H; Yin P; Dehm SM; Hart SN; Vedell PT; Barman P; Qin R; Mahoney DW; Carlson RE; Eckel-Passow JE; Atwell TD; Eiken PW; McMenomy BP; Wieben ED; Jha G; Jimenez RE; Weinshilboum R; Wang L
    PLoS One; 2015; 10(12):e0145176. PubMed ID: 26695660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-9 Acts as an OncomiR in Prostate Cancer through Multiple Pathways That Drive Tumour Progression and Metastasis.
    Seashols-Williams SJ; Budd W; Clark GC; Wu Q; Daniel R; Dragoescu E; Zehner ZE
    PLoS One; 2016; 11(7):e0159601. PubMed ID: 27447934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic reprogramming in prostate cancer.
    Ahmad F; Cherukuri MK; Choyke PL
    Br J Cancer; 2021 Oct; 125(9):1185-1196. PubMed ID: 34262149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NF-κB gene signature predicts prostate cancer progression.
    Jin R; Yi Y; Yull FE; Blackwell TS; Clark PE; Koyama T; Smith JA; Matusik RJ
    Cancer Res; 2014 May; 74(10):2763-72. PubMed ID: 24686169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series.
    Anselmino N; Labanca E; Shepherd PDA; Dong J; Yang J; Song X; Nandakumar S; Kundra R; Lee C; Schultz N; Zhang J; Araujo JC; Aparicio AM; Subudhi SK; Corn PG; Pisters LL; Ward JF; Davis JW; Vazquez ES; Gueron G; Logothetis CJ; Futreal A; Troncoso P; Chen Y; Navone NM
    Clin Cancer Res; 2024 May; 30(10):2272-2285. PubMed ID: 38488813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.
    Ding Z; Wu CJ; Chu GC; Xiao Y; Ho D; Zhang J; Perry SR; Labrot ES; Wu X; Lis R; Hoshida Y; Hiller D; Hu B; Jiang S; Zheng H; Stegh AH; Scott KL; Signoretti S; Bardeesy N; Wang YA; Hill DE; Golub TR; Stampfer MJ; Wong WH; Loda M; Mucci L; Chin L; DePinho RA
    Nature; 2011 Feb; 470(7333):269-73. PubMed ID: 21289624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer.
    Martens-Uzunova ES; Jalava SE; Dits NF; van Leenders GJ; Møller S; Trapman J; Bangma CH; Litman T; Visakorpi T; Jenster G
    Oncogene; 2012 Feb; 31(8):978-91. PubMed ID: 21765474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential.
    Miller ET; You S; Cadaneanu RM; Kim M; Yoon J; Liu ST; Li X; Kwan L; Hodge J; Quist MJ; Grasso CS; Lewis MS; Knudsen BS; Freeman MR; Garraway IP
    BMC Cancer; 2020 May; 20(1):398. PubMed ID: 32380981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.